We are live on ! Find out more
XBIT icon

XBiotech

55 hedge funds and large institutions have $14.5M invested in XBiotech in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 22 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

4% more funds holding

Funds holding: 5355 (+2)

0.79% less ownership

Funds ownership: 15.47%14.69% (-0.79%)

22% less capital invested

Capital invested by funds: $18.6M → $14.5M (-$4.12M)

59% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 22

Holders
55
Holders Change
+2
Holders Change %
+3.77%
% of All Funds
0.74%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
9
Reduced
22
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$4.17M -$28.8K -8,357 -0.6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$3.44M -$6.32K -1,832 -0.2%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$1.49M +$23.1K +6,703 +1%
State Street
4
State Street
Massachusetts
$744K
Northern Trust
5
Northern Trust
Illinois
$678K -$7.67K -2,225 -1%
BCM
6
Bridgeway Capital Management
Texas
$399K -$74.5K -21,598 -15%
Morgan Stanley
7
Morgan Stanley
New York
$342K -$58.2K -16,893 -14%
American Century Companies
8
American Century Companies
Missouri
$329K -$77.9K -22,587 -18%
Bank of New York Mellon
9
Bank of New York Mellon
New York
$295K
Millennium Management
10
Millennium Management
New York
$267K -$625K -181,166 -69%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$238K -$5.55K -1,609 -2%
Charles Schwab
12
Charles Schwab
California
$218K +$30.7K +8,918 +15%
Connor, Clark & Lunn Investment Management (CC&L)
13
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$211K -$31.1K -9,009 -12%
EF
14
Empowered Funds
Pennsylvania
$196K +$3.6K +1,043 +2%
Goldman Sachs
15
Goldman Sachs
New York
$153K -$22.6K -6,548 -12%
UBS Group
16
UBS Group
Switzerland
$124K -$28.3K -8,218 -18%
Deutsche Bank
17
Deutsche Bank
Germany
$98.3K
JP Morgan Chase
18
JP Morgan Chase
New York
$97.8K +$53.7K +15,561 +106%
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
$85.9K +$47.4K +13,749 +108%
N
20
Nuveen
North Carolina
$80.6K
National Bank of Canada
21
National Bank of Canada
Quebec, Canada
$80.3K
Barclays
22
Barclays
United Kingdom
$65.2K -$34.1K -9,896 -33%
RhumbLine Advisers
23
RhumbLine Advisers
Massachusetts
$63.1K -$955 -277 -1%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$56.4K +$60K +17,400 New
BNP Paribas Financial Markets
25
BNP Paribas Financial Markets
France
$52.9K -$3.64K -1,055 -6%

XBIT Hedge Fund Activity: Q1 2025 in Review

55 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2025, worth a combined $14.5M — down 22% from $18.6M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new XBIT positions and 6 closed out — a net gain of 2 holders — while 9 added to existing stakes and 22 trimmed.

The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $60K. The largest seller was Millennium Management, cutting an estimated $625K.

  • 55 institutional investors held XBiotech (XBIT) as of Q1 2025, up from 53 in Q4 2024.
  • Funds reported $14.5M of XBiotech stock for Q1 2025, down 22% quarter-over-quarter.
  • 8 funds opened new XBiotech positions in Q1 2025 and 6 closed out, a net change of +2 holders.
  • The largest XBiotech buyer in Q1 2025 was Two Sigma Advisers, an estimated $60K added.
  • The largest XBiotech seller in Q1 2025 was Millennium Management, an estimated $625K sold.

Based on aggregated 13F filings for Q1 2025.